| Abstract | Psoriasis is a chronic inflammatory skin disease of unknown etiology. An immune-reaction mediated by T lymphocytes is important in the pathogenesis. Cyclosporin is a selective immuno-suppressant that inhibits helper T lymphocytes. Several controlled clinical studies have shown that cyclosporin is highly effective in controlling severe psoriasis. The main side effects are hypertension, nephrotoxicity and increased risk of developing malignancies, particularly after long-term treatment. Side effects during short-term therapy appear to be reversible. Some questions connected to the long-term use and safety of cyclosporin are still unsolved. |
| Authors | J R Bjerke
(Affiliation: Hudavdelingen, Medisinsk klinikk, Ullevål sykehus, Oslo.)
|
| Journal | Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
(Tidsskr Nor Laegeforen)
Vol. 112
Issue 22
Pg. 2863-5
(Sep 20 1992)
ISSN: 0029-2001 NORWAY |
| Vernacular Title | Cyklosporin i behandlingen av psoriasis. |
| PMID | 1412327
(Publication Type: English Abstract, Journal Article)
|
| Chemical References |
|
| Topics |
- Cyclosporine
(adverse effects, pharmacokinetics, therapeutic use)
- Humans
- Psoriasis
(drug therapy, immunology, pathology)
|
